Company intelligence / Profile preview

BeOne Medicines

Ownership: Public · BEIGF
Employees: ~11000
Development stage: Commercial

Overview

BeOne Medicines has developed several approved cancer treatments including Tevimbra (tislelizumab), a PD-1 inhibitor approved for multiple indications, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase inhibitor that has become a blockbuster drug with $1.3 billion in sales in the last financial year[8]. Recent FDA approvals include Tevimbra for first-line treatment of advanced esophageal squamous cell carcinoma in combination with chemotherapy (March 2025)[3].

Therapeutic areas: OncologyHematology
Modalities: Monoclonal antibodiesPD-1 inhibitorsBruton's tyrosine kinase inhibitors
Industry: Biotech

Drug pipeline

21 assets

sonrotoclax

Approved

20 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on BeOne Medicines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BeOne Medicines.

Explore the full profile